Literature DB >> 3082276

The chemotherapeutic potential of polyamine antimetabolites.

A N Kingsnorth.   

Abstract

The polyamines, putrescine, spermidine and spermine are small cationic molecules essential for DNA synthesis and cell replication. Because the cytotoxicity of most anti-cancer drugs can be attributed to inhibitory effects on DNA synthesis and cell replication it led to speculation that inhibition of polyamine synthesis could be a useful tool in the control of neoplastic growth. In 1978 alpha-difluoromethylornithine (DFMO), a powerful inhibitor of ornithine decarboxylase, the rate limiting enzyme in polyamine synthesis, was synthesized by Metcalf. Since then numerous investigators have tested the potential of DFMO and other polyamine antimetabolites as chemotherapeutic agents in experimental animals and cell cultures. The accumulated knowledge is now being evaluated in the treatment of human proliferative disorders and cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082276      PMCID: PMC2497796     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  46 in total

Review 1.  Polyamines in rapid growth and cancer.

Authors:  J Jänne; H Pösö; A Raina
Journal:  Biochim Biophys Acta       Date:  1978-04-06

Review 2.  Use of polyamine antimetabolites in experimental tumours and in human leukemia.

Authors:  J Jänne; L Alhonen-Hongisto; P Seppänen; M Siimes
Journal:  Med Biol       Date:  1981-12

3.  In vitro induction of ornithine decarboxylase in urinary bladder carcinoma cells.

Authors:  K Izumi; Y Hirao; L Hopp; R Oyasu
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

4.  Decreased cytotoxicity of aziridinylbenzoquinone caused by polyamine depletion in 9L rat brain tumor cells in vitro.

Authors:  L Alhonen-Hongisto; D F Deen; L J Marton
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

5.  Polyamines in colorectal cancer.

Authors:  A N Kingsnorth; A B Lumsden; H M Wallace
Journal:  Br J Surg       Date:  1984-10       Impact factor: 6.939

6.  Polyamine biosynthesis and interconversion in rodent tissues.

Authors:  A E Pegg; J E Seely; H Pösö; F della Ragione; I A Zagon
Journal:  Fed Proc       Date:  1982-12

Review 7.  Polyamine metabolism and function.

Authors:  A E Pegg; P P McCann
Journal:  Am J Physiol       Date:  1982-11

8.  Effects of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene.

Authors:  J R Fozard; N J Prakash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

9.  Mutant strain of Chinese hamster ovary cells with no detectable ornithine decarboxylase activity.

Authors:  P Pohjanpelto; E Hölttä; O A Jänne
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

10.  Modulation of the tissue disposition of methylglyoxal bis(guanylhydrazone) in mice by polyamine depletion and by polyamine administration.

Authors:  A Kallio; P Seppänen; L Alhonen-Hongisto; J Jänne
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

View more
  3 in total

1.  Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis.

Authors:  M A Cornbleet; A Kingsnorth; G P Tell; K D Haegele; A M Joder-Ohlenbusch; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Authors:  Altaf Mohammed; Naveena B Janakiram; Venkateshwar Madka; Rebekah L Ritchie; Misty Brewer; Laura Biddick; Jagan Mohan R Patlolla; Michael Sadeghi; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-23

3.  Mucosal polyamine metabolism in the columnar lined oesophagus.

Authors:  M R Gray; H M Wallace; H Goulding; J Hoffman; W E Kenyon; A N Kingsnorth
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.